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Mutations in the never-in-mitosis A-related kinase, Nek8, are associated with cystic kidney disease in both
humans and mice, with Nek8 being the NPHP9 gene in the human juvenile cystic kidney disease, nephro-
nophthisis. Human Nek8/NPHP9 localizes to centrosomes and the proximal region of cilia in dividing and cili-
ated cells, respectively. However, the regulation of Nek8 kinase activity, as well as its role in ciliogenesis,
remains to be deﬁned. Here, by establishing Nek8 kinase assays, we ﬁrst demonstrate that the localization
of Nek8 to centrosomes and cilia is dependent on both kinase activity and the C-terminal non-catalytic
RCC1 domain. The kinase domain alone is active, but does not localize correctly, while the RCC1 domain
localizes correctly and can be phosphorylated by Nek8. We propose that centrosome recruitment is mediated
by the RCC1 domain, but requires a conformational change in the full-length protein that is promoted by
autophosphorylation. Interestingly, three human NPHP9-associated mutants retain full kinase activity.
However, only two of these, L330F and A497P, localize correctly, suggesting that the third mutant, H425Y,
disrupts a centrosome targeting sequence in the RCC1 domain. Importantly, we ﬁnd that induction of cilio-
genesis upon cell cycle exit is accompanied by both activation and proteasomal degradation of Nek8, and
that activation is dependent upon phosphorylation within the catalytic domain. Taken together, these ﬁnd-
ings reveal important insights into the mechanisms through which Nek8 activity and localization are regu-
lated during ciliogenesis.
INTRODUCTION
Nephronophthisis (NPHP) is a rare, early-onset, cystic kidney
disease. It is one type of a wider spectrum of inherited diseases
that share many clinical symptoms and are collectively known
as ciliopathies. In these diseases, the underlying cellular defect
is in the generation, organization or function of a specialized
organelle, called the primary cilium. Primary cilia are small
hair-like projections present on most cells of the human
body. They act as antennae to detect extracellular mechanical
and chemical signals that are then transduced via intracellular
signalling pathways to give coordinated responses, including
proliferation and differentiation (1,2). It is now understood
that these responses are crucial to development and homeosta-
sis in multicellular organisms explaining why defects in this
structure underlie human ciliopathies (3–5).
Morphologically, the primary cilium, which is largely
analogous to the ﬂagella in different biological systems,
consists of a plasma membrane extension that surrounds a
microtubule axoneme. The axoneme itself is composed of a
cylindrical ring of nine microtubule doublets that extend out
from the distal end of a basal body that sits at the cytoplasmic
surface. The connection between the basal body and the
axoneme is known as the transition zone and is the region
where proteins enter or exit from the cilium, often trafﬁcked
in an active manner by the intraﬂagellar transport machinery.
Basal bodies, being short cylinders of nine microtubule
triplets, are analogous in structure to centrioles that are
found within the centrosome, the primary microtubule organ-
izing centre of higher eukaryotes. Indeed, basal bodies and
centrioles are interchangeable structures; in proliferating
cells, the centrioles sit within the centrosome and anchor the
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bules both in interphase and mitosis, while upon exit from
the cell cycle and entry into quiescence, the centrioles move
to the cell surface and start to act as basal bodies. Here, the
older one of the pair, previously the mother centriole, attaches
to the membrane via its distal appendages and initiates
the growth of the axonemal microtubules directly from its
distal end (6).
Ciliopathies are associated with a wide and diverse spec-
trum of clinical phenotypes that include retinal degeneration,
left–right asymmetry defects, polydactyly, anosmia, mental
retardation and obesity. However, one of the most common
defects seen in most ciliopathies is cystic dilatation of
tubules that develop in the kidney as a result of failure to
detect ﬂow through the tubules of these organs. Autosomal
dominant polycystic kidney disease (ADPKD) is the most
common monogenic disorder known to man, with a frequency
of 1:400–1:1000. It is caused by mutations in the PKD1 or
PKD2 genes that encode the primary cilium membrane
proteins, polycystin-1 (PC-1) and polycystin-2 (PC-2),
respectively (7). Autosomal recessive PKD (ARPKD) on the
other hand is rare and results from mutations in the PKHD1
gene that encodes a transmembrane protein, ﬁbrocystin/poly-
ductin, that localizes to the cilium and centrosome in renal
epithelial cells.
NPHP represents a distinct autosomal recessive kidney
disease that tends to be early onset and is the main genetically
deﬁned cause of end-stage renal failure within the ﬁrst three
decades of life (8). Unlike PKD, where an increasing
number of large kidney cysts lead to severely enlarged
kidneys, NPHP is characterized by tubular basement mem-
brane thickening, tubular atrophy, tubulointerstitial nephritis
and, eventually, cyst-like structures at the junction of the
cortex and medulla. So far, 11 distinct NPHP loci have been
identiﬁed whose mutation causes this disease, while mutations
in at least 7 other genes, including those that are causative for
Joubert Syndrome (JBTS), Meckel-Gruber Syndrome (MKS)
and Senior-Loken Syndrome, give highly related clinical
phenotypes (9). However, advanced sequencing strategies
revealed that mutations in known NPHP-related genes were
identiﬁed in only 25% of 120 patients, suggesting that a
large number of causative genes are yet to be identiﬁed (10).
Indeed, a recent proteomic analysis deﬁned a network of
proteins interacting with NPHP, JBTS and MKS proteins,
and patient DNA sequencing identiﬁed two new NPHP–
JBTS genes (11).
One of the NPHP genes, NPHP9, encodes the never-in-
mitosis A (NIMA)-related kinase, Nek8. This protein has an
N-terminal catalytic domain typical of serine/threonine
kinases and a C-terminal domain that bears homology to the
seven-bladed b-propeller of the RCC1 GTPase exchange
factor. The NIMA-related kinases, or Neks, represent a large
family of 11 serine/threonine protein kinases, named Nek1
to Nek11, that are related to the mitotic regulator, NIMA, of
the ﬁlamentous fungus, Aspergillus nidulans (12). Like their
fungal counterpart, the human kinases have mainly been
studied in relation to their role in cell cycle progression. In
particular, Nek2, Nek6, Nek7 and Nek9 clearly function in
mitosis, contributing to the separation of centrosomes and es-
tablishment of a robust microtubule-based mitotic spindle.
Interestingly, though, studies of NIMA-related kinases in
other lower eukaryotes, notably Chlamydomonas and Tetrahy-
mena, revealed potential roles in cilia length control, as well as
coordination of ciliogenesis with cell cycle progression (13–
15). In this sense, the fact that some Neks play roles in centro-
some regulation in mitosis, while others regulate basal body
function during ciliogenesis is intriguing and suggests an
underlying conserved role in regulation of microtubule organ-
ization.
In 2000, the mutation that was causative for two mouse
models of polycystic kidney disease, named kat (for kidney,
anemia, testis) and kat
2J, was mapped to the murine Nek1
gene (16,17). This was the ﬁrst clue that mammalian Neks
may have a role in ciliogenesis. Nek1 has since been localized
to centrosomes and the primary cilium and has recently been
found to be mutated in a human ciliopathy, short-rib polydac-
tyly syndrome type Majewski (18–21). Subsequent to the
identiﬁcation of the mouse Nek1 PKD model, a missense
mutation (G448V) in the non-catalytic domain of Nek8 was
identiﬁed in the jck (juvenile cystic kidney) mouse model of
autosomal recessive juvenile PKD (22). The kidneys of
these mice had signiﬁcantly lengthened cilia, suggesting that
Nek8 might also play a role in ciliary length control (23,24).
Otto et al.( 25) then reported three NPHP families in which
mutations in human Nek8 were detected. These included a
homozygous H425Y mutation, a heterozygous A497P muta-
tion and a heterozygous L330F mutation that was present in
a patient that also had a homozygous mutation in NPHP5.
The fact that, in two cases, only heterozygous mutations
were found in what is a recessive disease suggests that Nek8
may act as a modiﬁer gene in renal and eye pathologies, and
be inherited in an oligogenic manner.
Nek8 localizes to the primary cilium, speciﬁcally to the
proximal region of the cilium that sits just above the transition
zone (24,26). This region, which has been named the inversin
compartment, is the site at which another NPHP-disease gene,
Inv/NPHP2, is localized. In fact, Inv/NPHP2 appears to anchor
NPHP3 and Nek8/NPHP9 to this location (26). Other proteins
encoded by NPHP-disease genes, including NPHP1, NPHP4
and NPHP8/RPGRIP1L, localize more precisely to the transi-
tion zone, below the region where Nek8/NPHP9, Inv/NPHP2
and NPHP3 localize. Moreover, in Chlamydomonas, the
NPHP6/CEP290 homologue localizes to the wedge-shaped
structures that connect the ﬂagellar membrane with the
axonemal microtubule doublets in the transition zone; and
mutation leads to an abnormal distribution of proteins within
the ﬂagella (27). This has led to the hypothesis that the
NPHP proteins may exist in one or several complexes
around the transition zone that act as gatekeepers to control
protein entry and exit from the cilium (28,29).
To date, the kinase activity of Nek8 has not been reported.
For this reason, it is difﬁcult to know whether mislocalization
of certain Nek8/NPHP9 point mutants is a result of loss of
activity. Similarly, it is unclear what role kinase activity has
in Nek8 localization, although a point mutant in the mouse
Nek8 kinase domain that is predicted to cause loss of activity
prevented Nek8 from localizing to cilia (30). Here, we set out
to establish an assay that would allow us to measure Nek8
kinase activity in mammalian cells. From this, we propose a
model for how activity regulates Nek8 localization based on
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catalytic RCC1-like domain is required to expose a ciliary-
targeting site present within this domain. Our studies also
reveal that Nek8 mutations identiﬁed in NPHP patients do
not alter activity. Finally, we show that the onset of ciliogen-
esis is accompanied by activation and proteasomal mediated
degradation of Nek8.
RESULTS
Establishment of an assay for Nek8 protein kinase activity
As we wanted to explore the mechanism of Nek8 regulation
and how kinase activity might be important for Nek8 func-
tion, we ﬁrst needed to establish conditions under which
Nek8 activity could be measured. For this purpose, we
began by performing in vitro kinase assays using a commer-
cial source of puriﬁed GST-tagged Nek8 kinase expressed in
wheat germ extract. Using myelin basic protein (MBP),
histone H1 or b-casein as model substrates, we found that
Nek8 could phosphorylate all these proteins in the presence
of 4 mM ATP (Supplementary Material, Fig. S1A and B).
The related kinase, Nek9, was shown to require pre-
incubation with ATP to activate the kinase before it was
capable of phosphorylating exogenous substrates (31). In
the case of Nek8, though, we did not ﬁnd that pre-incubation
of the commercial kinase with ATP signiﬁcantly changed its
activity towards these proteins (Supplementary Material,
Fig. S1C and D). We then moved on to measure the
kinase activity of recombinant GFP-tagged Nek8 expressed
in HEK 293 cells. As controls, we generated two different
mutants; the ﬁrst, Nek8-K33R/D128A, had changes in two
key catalytic residues that we predicted would lead to loss
of activity, and the second, Nek8-T162E, in the activation
loop of the catalytic domain, which might be constitutively
active. Following transient expression, these proteins were
immunoprecipitated with anti-GFP antibodies and incubated
under the same assay conditions as the commercial kinase.
Figure 1. Establishment of Nek8 kinase activity assay. (A) HEK 293 cells were either mock transfected (2) or transiently transfected with GFP-tagged Nek8
constructs, as indicated, for 24 h before cells were lysed and immunoprecipitates prepared with anti-GFP antibodies. The amount of kinase precipitated was
determined by western blot with anti-GFP antibodies (IP-Blot) and the immunoprecipitates used for kinase assays with b-casein, Histone H1 or MBP as sub-
strates. Samples were analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS–PAGE), Coomassie Blue staining (CB) and autoradiog-
raphy (
32P). (B) Kinase activity of Nek8 proteins relative to the wild-type against the different substrates are shown. Data represent means (+SD) of three
separate experiments.
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capable of phosphorylating b-casein and histone H1, while
the T162E mutant showed elevated activity against these
substrates (Fig. 1A and B). However, MBP was equally
phosphorylated by all three Nek8 constructs, suggesting
that this phosphorylation may be attributable to a
contaminating kinase. Importantly, while we again found
that pre-incubation of the immunoprecipitates with ATP did
not alter Nek8 activity, we did ﬁnd that freezing cell extracts
prior to immunoprecipitation led to much reduced activity
(data not shown). We therefore conclude that, using these
conditions, recombinant Nek8 activity can be assayed follow-
ing expression in human cells.
NPHP-disease mutants of Nek8 are active
We then used this assay to determine the kinase activity of the
three NPHP-disease mutants of Nek8, L330F, H425Y and
A497P, previously identiﬁed in an analysis of 188 NPHP
patients (25). These were generated as GFP-tagged full-length
Nek8 constructs for expression in cells (Fig. 2A). In addition,
we generated a Nek8-G442V mutation, which was equivalent
to the G448V mutation identiﬁed in jck mice, an A197P muta-
tion, which is an amino acid change reported as a potential
drivermutationinpancreaticcancer(32),andaT162Amutation
to block phosphorylation at this site within the activation loop.
Following expression in HEK 293 cells, these proteins were
immunoprecipitated and their activity measured against
histone H1 as substrate. All the NPHP-disease mutants, as
well as the jck equivalent mutation, G442V, exhibited similar
activity to the wild-type protein (Fig. 2B and C). The A197P
pancreatic cancer mutant had slightly reduced activity; in con-
trast, the T162A mutant was completely inactive. We conclude
that Nek8 activity is most likely regulated through activation
loop phosphorylation and that the NPHP-disease mutants
identiﬁed to date do not lead to loss of kinase activity.
We next generated GFP-tagged fragments of Nek8
representing the kinase domain alone (GFP-Kin) or the
non-catalytic RCC1-like domain (GFP-RCC1). Following
expression and immunoprecipitation from HEK 293 cells, we
found that the isolated kinase domain showed similar levels of
activity to the wild-type protein, while the RCC1 domain had
no activity, as expected (Fig. 2D and E). While observing sub-
strate phosphorylation by Nek8, weak autophosphorylation
was sometimes apparent. We therefore tested whether the
commercial Nek8 kinase was capable of phosphorylating
the C-terminal RCC1 domain. Using immunoprecipitates
from HEK 293 cells transfected either with GFP alone or
GFP-RCC1asthesubstrate,wefoundthatNek8veryefﬁciently
phosphorylated the RCC1 domain (Fig. 2F). We therefore con-
clude that, under these conditions, the kinase domain alone is
sufﬁcient for activity, the kinase domain can phosphorylate
the RCC1 domain in trans and the RCC1 domain is not inhibi-
tory of activity in the full-length kinase.
Localization of Nek8 to centrosomes and cilia is dependent
on kinase activity and the RCC1 domain
Having established the activity of the different Nek8 con-
structs, we next examined their localization, speciﬁcally in
terms of their ability to localize to centrosomes in dividing
cells and cilia in serum-starved quiescent cells. For these
experiments, the Nek8 proteins were expressed in human
hTERT-RPE1 cells, as they form primary cilia upon serum
starvation and exit from the cell cycle. As previously found
in mouse IMCD-3 cells (30), the wild-type Nek8 protein loca-
lized to centrosomes during interphase of dividing cells and to
the proximal region of the cilia in ciliated cells, whereas the
catalytically inactive mutant failed to localize to either of
these sites (Fig. 3A–D). Moreover, in line with our activity
measurements, the T162A mutant did not localize to centro-
somes or cilia, while the T162E mutant did (Fig. 3A–D).
Taken together, these data provide persuasive evidence that
Nek8 kinase activity is essential to enable correct localization
at centrosomes and cilia.
It has previously been reported that at least some of the
NPHP-disease mutants exhibit aberrant localization (25).
Having established that all the disease mutants are active and
that activity is key to localization, were-investigated the localiza-
tion of these mutants. We found that the L330F and A497P
mutants localize correctly at centrosomes and cilia, whereas the
H425Y and G442V mutants do not (Fig. 3A–D). Interestingly,
the A197P mutation discovered in pancreatic cancer also
exhibited loss of localization from centrosomes and cilia
(Supplementary Material, Fig. S2A and B). This indicates
that activity alone is insufﬁcient for correct localization. We
therefore examined the localization of the isolated kinase
domain and RCC1 domain fragments. In this case, we found
that the RCC1 domain localized to centrosomes and cilia,
while the kinase domain alone, despite being active, did not
(Fig. 4A–D). Taken together, we conclude that the correct
localization of full-length Nek8 to centrosomes and cilia
requires Nek8 catalytic activity, but that the centrosome/cilia-
targeting motif is present within the non-catalytic RCC1
domain. This provides an explanation for why some muta-
tions, but not others, in the RCC1 domain disturb localization.
Moreover, as the two mutants that disturb localization, H425Y
and G442V, lie close together, we propose that they likely fall
within the same targeting motif.
Nek8 proteins also localize to the nucleus
While observing the localization of recombinant Nek8 to the
centrosome, we noted that the non-centrosomal pool of
protein tended to be equally distributed between the cytoplasm
and nucleus. This was also true of the endogenous protein as
indicated with a polyclonal antibody that we raised to Nek8,
which also showed localization to centrosomes and the prox-
imal region of cilia (Fig. 5A and Supplementary Material,
Fig. S3A and B), and for both GFP-Nek8 and Flag-Nek8
(Fig. 5B and data not shown). To test whether this was a regu-
lated event, cells transfected with GFP-Nek8 were treated with
leptomycin B, an inhibitor of Crm1-mediated nuclear export.
This led to enhanced intensity of the nuclear localization, in-
dicating that Nek8 normally undergoes nuclear-cytoplasmic
shuttling (Fig. 5B). We next determined whether the kinase
domain or NPHP-disease mutants were altered in their
ability to localize to the nucleus. None of the mutations in
the kinase domain affected nuclear localization, indicating
that activity is not required for nuclear uptake. However,
1158 Human Molecular Genetics, 2012, Vol. 21, No. 5Figure 2. NPHP-disease mutants of Nek8 retain full kinase activity. (A) Schematic diagram of Nek8 showing the N-terminal kinase and C-terminal RCC1-like
domains. The start and end positions as well as the amino acids mutated in this study are indicated. (B). Kinase assays were performed and analysed as described in
Figure1onimmunoprecipitatespreparedfromHEK293cellstransfectedfor24 hwiththeconstructsindicatedandusinghistoneH1assubstrate.(C)Thekinaseactivity
of the different Nek8 proteins relative to the wild-type is indicated. (D) Kinase assays were performed and analysed as described in Figure 1 on immunoprecipitates
prepared from HEK 293 cells that were either mock-transfected or transfected for 24 h with wild-type Nek8, the kinase domain fragment (Kin) or the RCC1 domain
fragment (RCC1). (E) The kinase activity of the different Nek8 proteins relative to the wild-type is indicated. (F) HEK 293 cells were transiently transfected with
GFP alone or GFP-RCC1 for 24 h before cells were lysed and immunoprecipitates prepared with anti-GFP antibodies. Immunoprecipitates were then subject to
western blotwith anti-GFP antibodies (IP-Blot) or used inkinase assayswith the commercial Nek8protein. Kinase assayswere then subject to SDS–PAGEan da ut o-
radiography (
32P). Data in (C) and (E) represent means (+SD) of three separate experiments. Molecular weights (kDa) are indicated on the left of gels in (D) and (F).
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nucleus, the H425Y and G442V mutants were both excluded
from the nucleus (Fig. 5C and D). The A197P pancreatic
mutant also failed to localize to the nucleus (Supplementary
Material, Fig. S2C). Upon testing the isolated fragments, we
found that the kinase domain alone was excluded consistent
with activity not being the key determinant of nuclear
uptake, whereas the RCC1 domain did localize to the
nucleus (Fig. 5E and F). We interpret these data to mean
that one or more nuclear localization sequences (NLS) are
present within the non-catalytic RCC1 domain, but that
these are disturbed by a number of NPHP point mutations,
as well as for some reason, the A197P mutation in the
kinase domain.
Nek8 undergoes proteasomal degradation in response
to quiescence
During these studies into Nek8 localization, we noted that it
was difﬁcult to ﬁnd transiently transfected cells following
serum starvation of hTERT-RPE1 cells. Indeed, calculation
of transfection efﬁciency by immunoﬂuorescence microscopy
revealed that, relative to the level seen after 24 h without
serum starvation, there was a 5-fold decrease in cells trans-
fected after 24 h serum starvation (Fig. 6A). This loss,
which was speciﬁc to the GFP-Nek8 protein as it was not
seen with GFP alone or GFP-Nek2 (data not shown), was
conﬁrmed by western blot analysis (Fig. 6B). To determine
whether the sudden loss of Nek8 protein was due to
proteasome-mediated degradation, transfected cells were
treated with the proteasome inhibitor, MG132, for 4 h follow-
ing 20 h of serum starvation. This led to a dramatic recovery
of both number of transfected cells observed by immunoﬂuor-
escence microscopy and protein abundance by western blot
(Fig. 6A and B). Using Nek8 antibodies, we found that en-
dogenous Nek8 protein also underwent proteasomal degrad-
ation upon serum starvation of hTERT-RPE1 cells (Fig. 6C).
We wanted to know whether this was a cell cycle response
due to entry into quiescence, or a signalling response due to
growth factor withdrawal. For this purpose, we transfected
GFP-Nek8 into two cell lines, hTERT-RPE1 and NIH3T3,
that we conﬁrmed by ﬂow cytometry and BrdU incorporation
exited the cell cycle upon serum withdrawal, and two
cell lines, HeLa and U2OS, that remained in the cell
cycle despite serum withdrawal (Supplementary Material,
Fig. S4A–D). Strikingly, we found that the proteasomal-
dependent loss of Nek8 only occurred in the cell lines that
entered quiescence, and not in those that remained in the
cell cycle (Fig. 6D). We then used the different mutant con-
structs to test whether kinase activity was required for protea-
somal degradation and whether the NPHP-disease-associated
mutants were also degraded upon serum starvation. All full-
length Nek8 constructs were degraded in a proteasome-
dependent manner irrespective of whether they had activity
or not, or whether they were causative for disease or not (Sup-
plementary Material, Fig. S5A and B). Consistent with this,
we found that the kinase domain alone could be degraded in
a proteasome-dependent manner and again this was not
dependent on activity, as similar results were seen with the
kinase domain fragment into which the T162A mutation had
been introduced (Fig. 6E and F). Intriguingly, an upshift was
seen with the kinase domain fragment alone upon serum star-
vation that was not present with the T162A mutant, suggesting
that serum starvation is also accompanied by phosphorylation
at this residue. We therefore conclude that exit from the cell
cycle is accompanied by proteasome-mediated degradation
of Nek8 that occurs via targeting of the kinase domain but
in a kinase-independent manner.
Nek8 kinase is activated upon exit from the cell cycle
Due to the apparent phosphorylation of Nek8 that we had
detected upon serum starvation, we then asked whether
serum starvation led to a change in activity of the Nek8
kinase. For this purpose, we ﬁrst attempted to measure
GFP-Nek8 activity by immunoprecipitation from transfected
hTERT-RPE1 cells, as opposed to HEK 293 cells. Initial
attempts to detect Nek8 activity in this manner proved frustrat-
ing with similar levels of weak activity being detected with
both the wild-type and catalytically inactive Nek8 proteins.
However, when cells were serum starved, speciﬁc activity
from the wild-type, but not catalytically inactive mutant,
was detected despite the reduction in protein due to proteaso-
mal degradation (Supplementary Material, Fig. S6A and B).
We therefore repeated these experiments adding MG132 to
the serum-starved cells and conﬁrmed the dramatic activation
of Nek8 in response to exit from the cell cycle (Fig. 7A and
B). MG132 did not, on the other hand, stimulate Nek8 activity
in the absence of serum starvation (data not shown). Albeit
relatively weak, we were also able to detect signiﬁcant activa-
tion of endogenous Nek8 upon serum starvation of
hTERT-RPE1 cells (Supplementary Material, Fig. S6C). As
we had shown that all the NPHP-disease mutants were
active in HEK 293 cells, we tested whether there was any
change in activation of these proteins upon serum starvation
in hTERT-RPE1 cells. All three of the NPHP-disease-
associated mutants, together with the jck equivalent mutation
and the pancreatic cancer-associated mutation, showed
equivalent kinase activation to the wild-type protein (Supple-
mentary Material, Fig. S6D). Finally, as we had found that
Nek8 was most likely phosphorylated on T162 upon serum
starvation, we asked whether this activation might at least in
part be due to phosphorylation at this site. For this purpose,
we tested the relative activation of the wild-type and T162
Figure 3. Localization of Nek8 to centrosomes and cilia is dependent on kinase activity. (A) Asynchronous hTERT-RPE1 cells were transiently transfected for
24 h with GFP-Nek8 constructs, as indicated. They were ﬁxed in methanol and stained with antibodies against GFP to detect the recombinant Nek8 (green in
merge) and g-tubulin to detect the centrosome (red in merge). (B) The histogram shows the % cells with the GFP-Nek8 protein visible at the centrosome. (C)
hTERT-RPE1 cells were transiently transfected for 4 h with GFP-Nek8 constructs, as indicated, and then serum starved for 48 h to promote ciliogenesis before
methanol ﬁxation and staining with antibodies against GFP to detect the recombinant Nek8 (green in merge) and acetylated tubulin to visualize the cilia (red in
merge). (D) The histogram shows the % cells with the GFP-Nek8 protein visible at the primary cilium. In (A) and (C), DNA was stained with Hoechst 33258
(blue in merge); insets show enlargements of the cilia; scale bars, 10 mm. In (B) and (D), data represent mean (+SD) of three separate experiments where at least
45 cells were counted.
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T162A mutant exhibited very low activity and was not
further activated by serum starvation, whereas the T162E
mutant showed high activity but was also not further activated
(Fig. 7C and D). Moreover, the level of activity of the T162E
mutant in cycling cells was similar to that of the wild-type
protein after serum starvation. We therefore conclude that
exit from the cell cycle is accompanied by activation of
Nek8 that largely results from phosphorylation of T162 in
the activation loop of the kinase.
Figure 4. Localization of Nek8 to centrosomes and cilia is regulated by the RCC1 domain. (A) hTERT-RPE1 cells were either mock transfected or transiently
transfected for 24 h with GFP-Nek8-truncated constructs, as indicated. They were ﬁxed in methanol and stained with antibodies against GFP to detect the re-
combinant Nek8 (green in merge) and g-tubulin to detect the centrosome (red in merge). (B) The histogram shows the % cells with the GFP-Nek8 protein visible
at the centrosome. (C) hTERT-RPE1 cells were transiently transfected for 4 h with GFP-Nek8 constructs, as indicated, and then serum starved for 48 h to
promote ciliogenesis before methanol ﬁxation and staining with antibodies against GFP to detect the recombinant Nek8 (green in merge) and acetylated
tubulin to visualize the cilia (red in merge). (D) The histogram shows the % cells with the GFP-Nek8 protein visible at the primary cilium. In (A) and (C),
DNA was stained with Hoechst 33258 (blue in merge); insets show enlargements of the cilia; scale bars, 10 mm. In (B) and (D), data represent mean
(+SD) of three separate experiments where at least 45 cells were counted.
1162 Human Molecular Genetics, 2012, Vol. 21, No. 5DISCUSSION
Here, we describe an assay for Nek8 kinase activity that has
allowed us to explore the mechanisms through which this
protein implicated in the human juvenile cystic kidney
disease, NPHP, is regulated. We found that none of the
Nek8 mutations identiﬁed in NPHP patients, nor the equiva-
lent mutation to that found in the jck mouse model of juvenile
cystic kidney disease, alter activity of this enzyme. However,
kinase activity is required for correct localization of the
protein to the centrosome in dividing cells and the proximal
region of the cilia in quiescent cells. On the other hand, local-
ization is mediated via the non-catalytic RCC1 domain, and so
we propose that autophosphorylation within this domain may
be required to reveal a centrosome-targeting site. We also
show that exit from the cell cycle and initiation of ciliogenesis
is accompanied by, ﬁrst, activation and, second, degradation of
the Nek8 protein, while activation may require autophosphor-
ylation within the catalytic domain of the kinase. These studies
therefore provide important new insights into what regulates
both the activity and the localization of this ciliopathy
disease protein (Table 1).
We ﬁrst of all found that mutations not only of key catalytic
site residues (K33R and D128A) but also of a site on the ac-
tivation loop that is often subject to phosphorylation in
protein kinases, T162A in the case of Nek8, completely abol-
ished Nek8 kinase activity. Conversely, a T162E phosphomi-
metic mutant led to equivalent, possibly even elevated, Nek8
activity compared with the wild-type protein. We therefore
conclude that Nek8 is almost certainly regulated in a positive
manner through phosphorylation at this site. Secondly, we
found that an isolated kinase domain was as active as the full-
length protein arguing that, unlike the related Nek9 protein
(31), either the RCC1-like domain does not act as an auto-
inhibitory region, or the auto-inhibition is fully released
when the protein is expressed in cycling HEK 293 cells.
Thirdly, we found that the full-length kinase was capable of
phosphorylating an isolated RCC1-like domain raising the
prospect that this kinase undergoes autophosphorylation
within this region. When we looked at the localization of
these mutant and truncated proteins, we found that localization
to the centrosomes and cilia correlated precisely with activity
of the full-length proteins (active proteins localizing correctly
and inactive proteins failing to localize). Interestingly though,
the isolated RCC1-like non-catalytic domain localized correct-
ly but the isolated kinase domain did not. Taken together, we
propose a model whereby the RCC1-like domain contains a
centrosome/ciliary-targeting sequence, but that kinase activity
is also required, with autophosphorylation within the RCC1
domain potentially causing a conformational change that
reveals the centrosome-targeting site in the full-length
protein (Fig. 8A). The fact that localization of Nek8 to the
proximal region of the cilium was dependent on the Inv/
NPHP2 protein, which also regulates the localization of
NPHP3 to the same compartment (26), means that it will be
worthwhile testing whether the centrosome-targeting region
is forming a complex with one or both of these proteins.
NPHP is a recessive disease and therefore should result
from the loss of function of both alleles of an NPHP gene.
The H425Y mutant was identiﬁed in a homozygous state,
and we propose that it is the loss of correct subcellular target-
ing that leads to the disease. The loss of localization of this
mutant from cilia and centrosomes agrees with results
obtained by Otto et al.( 25). However, we also see loss of
this mutant from the nucleus and so whether the key defect
is loss of localization to centrosomes and cilia, or rather the
nucleus, is not clear. Nek8 does not contain an obvious NLS
suggesting that nuclear uptake is a result of either a cryptic
NLS or interaction with a partner that undergoes nuclear traf-
ﬁcking. In terms of ciliary targeting, while Nek8 does not
contain FR motifs or acidic clusters that could bind PACS-1
(33,34), it does contain two VxPx motifs that target PC-2
and other ciliary proteins to this structure (35–38). Although
these lie within the RCC1 domain construct used here, they
are found at the extreme N-terminus of this region immediate-
ly after the kinase domain and it is not clear how they would
be affected by the H425Y mutation. Moreover, these motifs
are not well conserved (Supplementary Material, Fig. S7).
Hence, although worthy of mutational analysis, it remains to
be shown whether they are functional or not.
It is intriguing that mislocalization to all three subcellular
sites is seen not only with the H425Y mutant but also with
the jck equivalent G442V mutation that lies within the same
RCC1 repeat. One can well imagine that centrosome and
ciliary targeting are regulated by interaction with one speciﬁc
partner protein, but could this also target the protein to the
nucleus? This possibility is supported by evidence that the
nuclear transport factors Ran and importin-b2 play a role in
the ciliary targeting of the microtubule motor protein KIF17
via a motif that can act as either a nuclear or ciliary localiza-
tion sequence (39). That the H425Y mutation does not just
lead to gross misfolding of the protein is supported by the
fact that it retains full kinase activity, and is activated and
degraded upon serum starvation in a similar manner to the
wild-type protein. On the other hand, our data suggest that
these latter activities are regulated through the kinase
domain and so it remains possible that this mutation does
cause a signiﬁcant disturbance to the predicted b-propeller
structure of the RCC1 domain. Structural modelling of the
Nek8 RCC1-like domain reveals that H425 lies within a con-
served motif that is commonly found in the loop between the
third and fourth b-strands of RCC1-like propeller blades
(Fig. 8B). The conformation adopted by this motif was
resolved in the third b-propeller of the E3 ubiquitin ligase
HERC2 in which the motif is found twice. This structure indi-
cates that the conserved histidine side chain forms an intramo-
lecular H-bond with the side chain of a conserved Ser or Thr
residue also present within this motif (Fig. 8C). Hence, muta-
tion of this residue to tyrosine is likely to disrupt the local
structure. Moreover, H425 and G442 lie within a surface
region of the protein that is strictly conserved among verte-
brates, as expected for a conserved interface (Fig. 8D, Supple-
mentary Material, Fig. S7 and Movie S1).
The L330F and A497P mutations were only detected in the
heterozygous state in NPHP patients. Moreover, the patient
carrying the L330F mutation was found to also carry a homo-
zygous mutation in NPHP5 (25). Our studies revealed no dif-
ferences in kinase activity, localization, activation or
degradation of these two mutants when compared with the
wild-type protein. This contradicts somewhat the results of
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mutants from cilia, but only loss of H425Y from centrosomes.
Their experiments though were carried out with mouse Nek8
in IMCD-3 kidney cells, whereas our experiments were per-
formed in human hTERT-RPE1 cells. Whether or not this is
the reason for the different results is not clear. However,
while it is possible that these mutations act as modiﬁers in
the presence of other bona ﬁde mutations, it remains to be
determined whether alone they are capable of causing NPHP.
Our studies identiﬁed two key mechanisms of Nek8 regula-
tion that accompanies entry into quiescence and induction of
ciliogenesis. First, the Nek8 kinase is activated. This correlates
with an upshift that is seen with the kinase domain alone, and
which is not seen with a T162A mutant. Furthermore, a T162E
mutant is as active in cycling cells as the wild-type protein is
after serum starvation. Thus, we propose that the increase in
Nek8 kinase activity is a result of activation loop phosphoryl-
ation speciﬁcally on T162. Whether this is the result of autop-
hosphorylation or an upstream kinase remains to be
determined. Secondly, the Nek8 protein undergoes degrad-
ation in a proteasome-dependent manner. This was shown
with recombinant GFP-Nek8, but not GFP alone, as well as
with the endogenous Nek8 protein. Interestingly, degradation
appeared to be mediated via the catalytic domain, as the
kinase domain alone was also degraded upon serum starvation,
but this was not dependent on activity as all full-length kinase
domain and disease-associated mutants were degraded. At the
present time, the purpose of Nek8 activation and degradation
remain entirely unknown. However, we can speculate that
Nek8 activity may be required to initiate some aspect of the
ciliogenesis programme, whereas its degradation may be
required to prevent this initiation process from being main-
tained indeﬁnitely.
Previous studies have reported that neither siRNA-mediated
depletion nor overexpression of Nek8 interferes with ciliogen-
esis (18,25,30). Understanding why mutation of Nek8 should
lead to cystic kidney disease therefore remains an enigma.
One possibility is that mislocalization disturbs the gatekeeper
function of protein complexes that include some of the NPHP
proteins and which localize around the transition zone (28,29).
This could lead to an imbalance in the localization of ciliary
proteins that control key developmental signalling pathways,
such as those mediated by the Hedgehog and Wnt ligands
(2,40,41). Similarly, it could disturb signalling via the poly-
cystins, PC-1 and PC-2, that are mutated in ADPKD.
Indeed, Nek8 is reported to interact with the PC-2 protein,
while the expression and localization of PC-1 and PC-2 are
disturbed in renal cells from the jck mouse (23,24). In add-
ition, mice that carry heterozygous mutations in both the
Pkd1 gene, which encodes PC-1, and the Nek8 gene also
develop a more aggressive form of cystic kidney disease
than are seen in Pkd1 heterozygotes alone (42). Interestingly,
Nek1 is also implicated in regulating PC-2 expression, in this
case through phosphorylation of an E3 ubiquitin ligase adaptor
that normally targets PC-2 for degradation (43).
Finally, our data with the A197P mutant raise some interest-
ing questions. This mutation lies within the catalytic domain
and was identiﬁed as a potential driver mutation in pancreatic
cancer (32), while overexpression of Nek8 has been reported
in breast tumours (44). While we found no dramatic alteration
in the kinase activity of this mutant, its ability to localize to the
centrosome, cilium and nucleus was completely abolished.
This could potentially abrogate a transcriptional programme
that dictates whether cells enter quiescence or continue
through the cell cycle. Indeed, defects in ciliary signalling to
the nucleus have now been implicated in the development of
tumours (45,46). Alternatively, Nek8 could play a role at cen-
trosomes during mitotic cell division and it is worth bearing in
mind that the development of kidney cysts reﬂects a loss of
control over cell cycle progression and, possibly, mitotic
spindle orientation (47–50). Recently, it was found that cells
from ARPKD patients that have mutations in the ﬁbrocystin/
polyductin protein exhibit centrosome ampliﬁcation and
mitotic spindle defects again linking cystic kidney disease for-
mation with mitotic defects (51). Moreover, whereas one study
did not detect Nek8 on centrosomes in dividing cells (18), we
and others clearly observed Nek8 on centrosomes throughout
the cell cycle and overexpression of Nek8 has been reported
to drive multinucleation, indicative of cell division failure
(22,30). It is possible then that, like certain other Neks includ-
ing Nek1 (52), Nek8 has functions in the DNA damage re-
sponse providing another reason for its nuclear localization.
Further studies are clearly required to address how Nek8
might coordinate ciliogenesis with the mitotic cell division
cycle.
MATERIALS AND METHODS
Plasmid constructions
Full-length Nek8 (residues 1–692), the kinase domain alone
(residues 4–258) and the RCC1 domain (residues 259–692)
were ampliﬁed by polymerase chain reaction using a full-
length human Nek8 cDNA obtained from the German cDNA
Consortium (RZPD) (clone DKFZp434NO419) as the tem-
plate. Ampliﬁed fragments were subcloned into the mamma-
lian expression vectors, pEGFP-T7 (53) and pFLAG-CMV-2
(Sigma), and the bacterial expression vector, pETM-11 (gift
from EMBL, Heidelberg), providing N-terminal GFP, Flag
or His tags, respectively. Site-directed mutagenesis was
Figure 5. Nek8 proteins shuttle to the nucleus in an RCC1-dependent manner. (A) Asynchronous hTERT-RPE1 cells were ﬁxed in methanol and stained with
antibodies against Nek8 (pre-immune sera, PI, top row; or immune sera bleed 4, B4, bottom row; green in merge) and g-tubulin to detect the centrosome (red in
merge). (B) hTERT-RPE1 cells were transiently transfected with GFP-Nek8 for 24 h and then treated without (2LMB) or with (+LMB) leptomycin B for 6 h
before being ﬁxed in methanol and stained with GFP antibodies to detect the recombinant Nek8 (green in merge) and Hoechst 33258 to stain the DNA. (C).
hTERT-RPE1 cells were transiently transfected for 24 h with the Nek8 constructs, as indicated before ﬁxation in methanol and staining with antibodies
against GFP to detect the recombinant Nek8 (green in merge) and g-tubulin to detect the centrosome (red in merge). (D) The histogram shows the % cells
with GFP-Nek8 either predominantly within the nucleus or with equal staining between cytoplasm and nucleus. (E) hTERT-RPE1 cells were transiently trans-
fected for 24 h with the Nek8 constructs as indicated and processed as in (C). (F) The histogram indicates nuclear localization of constructs analysed in (E). In
(A–C) and (E), DNA was stained with Hoechst 33258 (blue in merge); scale bars, 10 mm. Data in (D) and (F) represent mean (+SE) of three separate experi-
ments where at least 45 cells were counted.
Human Molecular Genetics, 2012, Vol. 21, No. 5 1165performed using the GenetailorTM Site-Directed Mutagenesis
System (Invitrogen) according to the manufacturer’s instruc-
tions. All constructs were veriﬁed by DNA sequencing
within the Protein and Nucleic Acid Laboratory (Leicester).
Antibody generation
For production of antibodies against Nek8, rabbits were
immunized with a His-tagged C-terminal fragment of Nek8
Figure 6. Serum starvation induces proteasomal degradation of Nek8. (A) The transfection efﬁciency (% cells positive for GFP-Nek8 as determined by immuno-
ﬂuorescence microscopy with GFP antibodies) in hTERT-RPE1 cells was determined at the times indicated after transfection (TF, hours), with or without serum
starvation (SS) and with or without MG132 treatment, as indicated. (B) hTERT-RPE1 cells were transfected with GFP alone or GFP-Nek8 for 48 h and SS and
treated with MG132, as indicated. Samples were analysed by SDS–PAGE and western blotting with antibodies against GFP and a-tubulin. (C) To observe
degradation of endogenous Nek8, hTERT-RPE1 cells were incubated as indicated before analysis by SDS–PAGE and western blotting with antibodies
against Nek8 and a-tubulin. (D) GFP-Nek8 was transfected into hTERT-RPE1, NIH 3T3, HeLa and U2OS cells. They were then incubated for 48 h with
serum or in serum-free media. Extracts were prepared and analysed for the amount of protein remaining after SS, when compared with in the presence of
serum, by SDS–PAGE and western blotting with anti-GFP antibodies. (E) hTERT-RPE1 cells were transfected for 48 h with the GFP-tagged Nek8 kinase
domain alone (GFP-Kin) and SS and treated with MG132, as indicated. Samples were analysed by SDS–PAGE and western blotting with antibodies against
GFP and a-tubulin. (F) hTERT-RPE1 cells were transfected for 48 h with GFP-tagged wild-type or T162A kinase domain construct and treated as indicated
before analysis by SDS–PAGE and western blotting with antibodies against GFP and a-tubulin. Data in (A) and (C) represent means (+SD) of three separate
experiments.
1166 Human Molecular Genetics, 2012, Vol. 21, No. 5spanning amino acids 270–550. This fragment was expressed
in E. coli strain Rosetta 2 (DE3) (Novagen) and puriﬁed
under denaturing conditions according to the standard
protocols. Immunizations and afﬁnity puriﬁcation of anti-
bodies were performed by Cambridge Research Biochem-
icals.
Figure 7. Cell cycle exit induces activation of Nek8. (A) hTERT-RPE1 cells were either mock transfected or transiently transfected with wild-type GFP-Nek8
(WT) or GFP-Nek8-K33R/D128A for 48 h and either left in normal media (left three lanes) or serum-starved (SS) for the ﬁnal 24 h with MG132 addition 4 h
prior to harvesting (right three lanes). Cells were then lysed and subjected to immunoprecipitation with anti-GFP antibodies. The amount of kinase precipitated
was determined by western blot with anti-GFP antibodies (IP-Blot) and the immunoprecipitates used for kinase assays with histone H1 as substrate. Samples
were analysed by SDS–PAGE, Coomassie Blue staining (CB) and autoradiography (
32P). (B) The kinase activity of Nek8 under different conditions against
histone H1 is shown relative to the activity for the wild-type kinase after SS. (C) hTERT-RPE1 cells were transfected with the GFP-tagged Nek8 constructs
indicated and processed as in (A). (D) The kinase activity of samples shown in (C) was determined as in (B). Data in (B) and (D) represent means (+SD)
of three separate experiments.
Table 1. Activity and subcellular localization of kinase domain and disease-associated mutants of Nek8
Nek8 constructs Kinase
activity
Centrosome Cilium Nucleus
Wild-type Nek8 WT Yes ++ +
Isolated fragments Kinase domain Yes 22 2
RCC1 domain No ++ +
NPHP9 mutations L330F Yes ++ +
H425Y Yes 22 2
A497P Yes ++ +
jck mutation G442V Yes 22 2
Catalytic mutants K33R/D128A No 22 +
T162A No 22 +
T162E Yes ++ +
Pancreatic cancer A197P Yes 22 2
The table summarizes the data obtained in this study on the kinase activity and subcellular localization of different Nek8 constructs based on expression of
GFP-tagged constructs in human hTERT-RPE1 cells. Kinase activity and localization to the centrosome and nucleus were determined in asynchronous dividing
cells, while localization to the primary cilium was determined in serum-starved ciliated cells. Note that of the three NPHP9-associated mutations, only one was
identiﬁed in a homozygous state, H425Y, which showed mislocalization from centrosomes, cilia and nuclei. The L330F and A497P mutations were identiﬁed as
heterozygous mutations and, as NHPH is a recessive disease and we saw no mislocalization of these mutants, it remains unclear what role they have in the disease.
Human Molecular Genetics, 2012, Vol. 21, No. 5 1167Figure 8. Models of Nek8 structure and regulation. (A) The schematic diagram shows how both kinase activity and the non-catalytic RCC1 domain may be
required for localization of Nek8 to centrosomes, cilia and possibly, nuclei. In this model, the wild-type protein undergoes autophosphorylation within the
RCC1 domain. It also undergoes phosphorylation within the activation loop of the catalytic domain, although whether this is an autophosphorylation event
is unclear. We propose that these phosphorylation events lead to an opening up of the conformation that reveals a centrosome-targeting sequence present
within the RCC1 domain (∗). However, a catalytically inactive mutant cannot autophosphorylate and hence remains in the closed conformation whereby the
centrosome-targeting sequence is masked. In an isolated RCC1 domain, the centrosome-targeting site would be unmasked and therefore not require phosphor-
ylation. (B) A structural model of the human Nek8 RCC1-like domain (residues 300–692) generated using Phyre and represented in Pymol is predicted to form a
7-bladed b-propeller, shown schematically (above left) and in cartoon representation (above right). The ﬁrst blade is formed from residues at the N- and C-
terminal ends of the domain, the other blades are formed sequentially, and each blade is composed of four beta-strands (below). Residues mutated in human
NPHP patients and in the jck mouse are shown as magenta spheres on the modelled structure (above right) and their positions within the blade are indicated
(below). (C) Residue H425 of Nek8 lies within a conserved motif that is commonly found in the loop between the third and fourth b-strands of RCC1-like
propeller blades (above). The conformation adopted by this motif was resolved in the third b-propeller of the E3 ubiquitin ligase HERC2 (PDB code 3KCI),
in which the motif is found twice. The region around residues 4220–4232 in HERC2 is representative (below), and reveals that the conserved histidine side
chain (magenta) forms a H-bond (dashed line) with the side chain of a conserved Ser or Thr residue (grey). (D) Four surface views of the human Nek8
RCC1 domain model related by 908 rotations around a vertical axis. With the exception of L330, H425, G442 and A497, which are coloured magenta, the
surface is coloured by sequence conservation (as deﬁned in Supplementary Material, Fig. S7): identical residues, red; conserved residues, orange; semi-conserved
residues, yellow; non-conserved residues, white. Conserved surface patches that include H425 and G442, which are absolutely conserved, are clearly visible in
the two central images, and there are no other extensive areas of surface conservation.
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Cells were grown in the following media: hTERT-RPE1 and
NIH 3T3 cells in Dulbecco’s modiﬁed Eagle’s medium
(DMEM)/Ham’s F12 (1:1) supplemented with 0.348%
sodium bicarbonate solution. HEK 293, HeLa and U2OS
cells were also gown in the DMEM medium. All cells were
supplemented with 10% fetal calf serum, 100 IU/ml penicillin
and 100 mg/ml streptomycin. Cells were grown at 378Ci na
5% CO2 atmosphere. Serum starvation was performed for
the times indicated by washing the cells 3× with 1×
phosphate-buffered saline (PBS) and replacing with the
serum-free medium. Transient transfections were performed
with Lipofectamine 2000 (Invitrogen), Fugene HD (Roche)
or according to the manufacturer’s instructions and analysed
after 24 or 48 h. MG132 (Sigma) and LMB (Calbiochem)
were added where indicated to a ﬁnal concentration of
10 mM and 40 nM, respectively.
Immunoﬂuorescence microscopy
Immunoﬂuorescence microscopy was carried out following
ﬁxation in cold methanol as previously described (54).
Primary antibodies were against Nek8 (1:250 dilution of
ﬁnal bleed), acetylated tubulin (0.5 mg/ml; Sigma), g-tubulin
(0.15 mg/ml, Sigma), GFP (0.5 mg/ml; Abcam) and Flag
(1:1000; Cell Signalling). Secondary antibodies were Alexa
Fluor 488- and 594-conjugated goat anti-mouse and goat anti-
rabbit IgGs (1 mg/ml, Invitrogen). Images were captured using
a TE300 inverted microscope (Nikon) or Leica TCS SP5 con-
focal microscope equipped with a Leica DMI 6000B inverted
microscope using a 63× oil objective (numerical aperture,
1.4). BrdU labelling was performed with the BrdU labelling
and detection kit II from Roche according to the manufac-
turer’s instructions.
Preparation of cell extracts, SDS–PAGE and western
blotting
For kinase assays, cells were lysed in NEB buffer (50 mM
HEPES-KOH,pH7.4,5 mMMnCl2,10m MMgCl2,5m Methyl-
ene glycol tetraacetic acid, 2 mM ethylene diamine tetraacetic
acid, 100 mM NaCl, 5 mM KCl, 0.1% (v/v) NP-40, 30 mg/ml
RNase A, 30 mg/ml DNase I, 10 mg/ml leupeptin, 10 mg/ml
bestatin, 10 mg/ml pepstatin, 1 mM PMSF, 20 mM
b-glycerophosphate, 20 mM NaF). For degradation
experiment, cells were washed once in PBS and lysed in lysis
buffer (50 mM Tris.HCl, pH 8.0, 0.5% Nonidet P-40, 150 mM
NaCl, 1 mM PMSF, 1×Protease Inhibitor Cocktail) for
30 min on ice. Lysates were centrifuged for 10 min,
13000 rpm, at 48C, and protein concentrations of the cleared
supernatant determined by the Bradford assay. Sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS–
PAGE),CoomassieBluestainingandwesternblottingwereper-
formed as previously described (55). For western blots of cell
lysates,20 mgoftotalproteinwasloadedperlane.Primaryanti-
bodieswereagainstNek8(1:250),a-tubulin(0.3 mg/ml;Sigma)
and GFP (0.5 mg/ml; Abcam). Secondary antibodies were
alkaline-phosphatase-conjugated anti-rabbit or anti-mouse
IgGs (1:7500; Promega) or horseradish peroxidase-labelled
IgGs (Amersham).
Immunoprecipitations
Four milligrams of transfected cell extracts were pre-cleared
for 30 min at 48C with protein G agarose beads (Sigma) that
had been pre-washed in NEB buffer. Beads were then
removed and supernatants incubated with GFP antibody
(1 mg/ml; Abcam) for 1 h on ice. The complexes were then
captured with protein G agarose beads (again pre-washed in
NEB buffer) O/N at 48C. Beads were then prepared for
further analysis by washing thrice in NEB buffer.
In vitro kinase assays
Kinase assays were carried out using either 25–30 mlo f
washed immune complex beads, prepared as described
above, or 0.1 mg of puriﬁed Nek8 kinase (Novus Biologicals;
Littleton, CO, USA). Brieﬂy, proteins were incubated with
5 mg of the appropriate substrate and 1 mCi of [g-
32P]-ATP
in 40 ml kinase buffer (50 mM Hepes-KOH, pH 7.4, 5 mM
MnCl2,5 m M b-glycerophosphate, 5 mM NaF, 4 mM ATP,
1m M DTT) for 30 min at 308C. To test the requirement for
Mg
2+, the MnCl2 was substituted for MgCl2. To test the re-
quirement for auto-activation, kinases were pre-incubated in
kinase buffer for 1 h at 308C prior to addition of substrate
and radiolabeled ATP. Reactions were stopped by addition
of 50 ml3 × Laemmli buffer and analysed by SDS–PAGE
and autoradiography. Substrate phosphorylation was quanti-
ﬁed by scintillation counting of protein bands excised from
dried gels. Excised bands were immersed in 3 ml Optiphase
HiSafe 2 liquid scintillant (Wallace-Perkin Elmer) and
amount of
32P incorporation determined by quantiﬁcation in
a LS6500 scintillation analyzer (Beckman Coulter).
Flow cytometry
Todeterminecellcycledistributions,cellpopulationsforanalysis
were harvested as appropriate, pelleted by centrifugation and
washed in 1× PBS before being resuspended in 1 ml 70%
ice-cold ethanol to ﬁx cells. Cells were maintained in ethanol at
48Cforaminimumof30 minbeforebeingstainedwithpropidium
iodide. Brieﬂy, cells were washed twice in 1× PBS to remove all
traces of ethanol, and resuspended in 1× PBS supplemented with
200 mg/ml RNase A and 20 mg/ml propidium iodide. Cells were
s t a i n e di nt h ed a r ka t4 8C for a minimum of 4 h. Cells were then
analysed via ﬂow cytometry, using a FACScan II instrument
and CellQuest Pro software (BD Biosciences).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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